key: cord-0922304-2lh5izp0
authors: Ngwe Tun, Mya Myat; Sakura, Takaya; Sakurai, Yasuteru; Kurosaki, Yohei; Inaoka, Daniel Ken; Shioda, Norifumi; Smith, Chris; Yasuda, Jiro; Morita, Kouichi; Kita, Kiyoshi
title: 5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
date: 2022-04-27
journal: Trop Med Health
DOI: 10.1186/s41182-022-00422-7
sha: d652f5e019095805723ba548fef20a49728a8063
doc_id: 922304
cord_uid: 2lh5izp0

The coronavirus disease 2019 (COVID 19) pandemic continues to pose a threat to global health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has spread rapidly worldwide and became dominant in many countries. A natural 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) has demonstrated antiviral activity in Wuhan, Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 infections in vitro. In this study, we report antiviral activity of 5-ALA, 5-ALA with SFC led to IC(50) of 329 and 765/191, respectively after infection with Omicron variant of SARS-CoV-2 in vitro. Our finding suggests that 5-ALA could be used as antiviral drug candidate to treat Omicron variant infected patients.

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have emerged a year and a half from the onset of coronavirus disease 2019 (COVID-19) pandemic. As of February 2022, Omicron variants have been divided into four distinct sub lineages: BA.1, BA.1.1, BA.2, and BA.3 [1] [2] [3] . The number of Omicron variant cases has increased in many regions of the world, spreading more easily than previously described SARS-CoV-2 isolates [4] . The Omicron variant has substantial spike protein mutations and is able to escape immune protection elicited by both vaccine and previous infection [5, 6] . Several direct-acting antivirals against COVID-19 have been approved or are under clinical development and can be divided in two categories; small molecules interfering with virus replication machinery, and monoclonal antibodies directed against the spike protein [7] . Aside from improving vaccinations against Omicron and future variants, we must develop new antiviral drugs [8, 9] . Antiviral drugs including remdesivir, molnupiravir, and nirmatrelvir inhibited SARS-CoV-2 Omicron variant infection [7, 10] . A natural amino acid, 5-aminolevulinic acid (5 ALA), is produced from most animals and plants which are present in food. In our previous studies, we reported antiviral activity of 5-ALA with or without sodium ferrous citrate (SFC) against the SARS-CoV-2 Wuhan strain and its variants including Alpha, Beta, Gamma and Delta strains [11, 12] . In this study, we evaluated the antiviral effect of 5-ALA with or without SFC against the SARS-CoV-2 Omicron variant in vitro. Vero E6 cells were treated with remdesivir or 5-ALA with or without SFC for 72 h (h) and then infected with SARS-CoV-2 Omicron variant (TY38-873, BA.1, provided by the Japan National Institute of Infectious Diseases) at a multiplicity of infection of 0.02. After 48 h post infection,

Tropical Medicine and Health the infected cell supernatants were harvested for viral RNA extraction [12, 13] . The SARS-CoV-2 antiviral assay is based on previously established specific quantitative real time PCR (qRT-PCR) [12] using cell supernatant RNA. The antiviral drug effect of remdesivir against the Omicron variant showed an IC 50 (virus inhibition by 50%) of 0.3 µM (Fig. 1A) . 5-ALA, 5-ALA and SFC inhibited SARS-CoV-2 Omicron variant infection in a dose dependent manner with an IC 50 of 329 and 765/191, respectively in vitro (Fig. 1B , C, Table 1 ). A cell viability assay was conducted in parallel with the antiviral assay [12, 13] and no cytotoxic effects were observed with CC 50 (cell survival by 50%) of 5-ALA > 2000 µM and of SFC > 500 µM in Vero E6 cells (Table 1 ). The Omicron variant which has notable mutations in the receptor binding domain of spike glycoprotein appears to be highly transmissible and less responsive to several of the currently used drugs [14] . Exogenously supplied 5-ALA prompted increased generation of protoporphylin IX (PPIX) and heme inside host cells, likely interfering with interaction of G-quadruplex (G4) structures [15] which inhibited SARS-CoV-2 infection. The G4 structure included in coronaviruses plays a key role in the genome replication/transcription [16] . 5-ALA with SFC is a supplement formulation registered in Japan as a food with functional claims. In a recent clinical study, Japanese patients with COVID-19 who were given 5-ALA and SFC capsules orally experienced a shorter time to recovery than that reported for patients who received only standard care for SARS-CoV-2 infection [17] . Recruitment for clinical trials on the effects of 5-ALA with SFC on COVID-19 outcomes in humans has been completed and the data is now being analyzed (Japan Registry of Clinical Trials CRB 7180001 and 3190006, respectively). Mitochondrial dysfunction has been reported as a cause of disorders in COVID-19 [18] . Given that 5-ALA activates the respiratory chain of mitochondria via heme bio-synthesis, maintenance of mitochondrial function is also expected to play a role in the effect of 5-ALA on the prevention and treatment of COVID and long COVID. In conclusion, we report the antiviral effects of 5-ALA with or without SFC on SARS-CoV-2 Omicron variant in vitro as a potential therapeutic and prophylaxis for COVID-19. 

Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2

Neutralization of the SARS-CoV-2 omicron BA.1 and BA.2 Variants

The race for coronavirus vaccines: a graphical guide

SARS-CoV-2 omicron variant: characteristics and prevention

The significant immune escape of pseudotyped SARS-CoV-2 variant omicron

Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern

Omicron: a drug developer's perspective

In silico screening of bioactive compounds of representative seaweeds to inhibit SARS-CoV-2 ACE2-bound omicron B.1.1.529 spike protein trimer

SARS-CoV-2 omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

5-Amino levulinic acid inhibits SARS-CoV-2 infection in vitro

Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2

The discovery of herbal drugs and natural compounds as inhibitors of SARS-CoV-2 infection in vitro

Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: a literature review

Targeting G-quadruplex DNA as cognitive function therapy for ATR-X syndrome

A G-quadruplex-binding macrodomain within the "SARS-unique domain" is essential for the activity of the SARScoronavirus replication-transcription complex

Tolerability, and efficacy of 5-aminolevulinic acid phosphate, an inducer of heme oxygenase 1, in combination with sodium ferrous citrate for the treatment of COVID-19 patients

SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE2

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Not applicable.